Related Experiment Video
Updated: Jan 28, 2026

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results
Susan R Rose1, Grafton Reeves2, Robert Gut3
1Departments of Pediatric Endocrinology and Metabolism, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.
Insights
Attention-deficit/hyperactivity disorder (ADHD) stimulant medication did not alter linear growth in children receiving growth hormone (GH) treatment. However, ADHD medication was associated with a greater BMI increase in patients with GH deficiency.
Area of Science:
- Pediatric Endocrinology
- Neurodevelopmental Disorders
Background:
- Growth hormone (GH) therapy is used for short stature in children.
- Attention-deficit/hyperactivity disorder (ADHD) is common in children and often treated with stimulant medication.
- The potential impact of ADHD stimulant medication on GH treatment outcomes requires investigation.
Purpose of the Study:
- To determine if ADHD stimulant medication influences linear growth in children undergoing GH treatment.
- To analyze the effect of concomitant ADHD medication on height standard deviation score (HSDS) and body mass index standard deviation score (BMI SDS) changes.
Main Methods:
- Analysis of data from the American Norditropin Studies: Web-Enabled Research Program.
- Comparison of linear growth in GH-treated children with and without ADHD stimulant medication.
- Use of linear mixed models to assess changes in HSDS and BMI SDS over 4 years.
- Matching of ADHD groups based on baseline characteristics to control for confounding factors.
Main Results:
- Linear growth (HSDS change) was similar between children receiving and not receiving ADHD stimulant medication when matched for baseline measurements.
- A slightly lower adjusted change in HSDS was observed in the ADHD medication group at years 1-4 before matching.
- A greater adjusted change in BMI SDS was observed in patients receiving ADHD stimulant medication, particularly those with GH deficiency.
Conclusions:
- ADHD stimulant medication does not appear to affect the linear growth response to GH treatment in children when baseline characteristics are considered.
- The increased BMI SDS in children with GH deficiency on ADHD medication warrants further research to understand the underlying mechanisms.
Objective:
To examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies: Web-Enabled Research Program.
Study Design:
Short, GH treatment-naive children with or without GH deficiency (GHD) received GH therapy. A subset also received ADHD stimulant medication (n = 1190), and others did not (n = 7230). Linear mixed models (adjusted means) examined height SDS (HSDS) and body mass index (BMI) SDS from baseline through year 4. Analyses were repeated with ADHD groups matched for baseline age, height, weight, BMI, and sex. Groups with and without GHD were compared between ADHD groups.
Results:
Adjusted change in HSDS for the group receiving ADHD stimulant medication was slightly lower than that for patients not receiving stimulant medication at years 1 to 4 (P < .05). However, adjusted change in HSDS was similar between children receiving and not receiving ADHD stimulant medication when matched for baseline measurements. At year 4, 86.7% of patients receiving ADHD stimulant medication, 86.8% of total patients not receiving ADHD stimulant medication, and 84.6% of matched group patients not receiving ADHD stimulant medication achieved HSDS >-2. Year 4 adjusted change in BMI SDS was greater in the patients receiving ADHD stimulant medication compared with both groups not receiving ADHD stimulant medication (P < .05). Patients with GHD showed comparable differences in adjusted change in BMI SDS among the ADHD groups at year 4, whereas patients without GHD showed no significant differences.
Conclusions:
ADHD medication did not affect the linear growth response of children treated with GH when those receiving or not receiving ADHD stimulant medication were matched for baseline measurements. Underlying reasons for the observed greater increase in BMI in patients with GHD concomitantly treated with ADHD medication remain to be elucidated.
Trial Registration:
ClinicalTrials.gov: NCT01009905.
More Related Videos
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Plant Hormones
Types of Hormones
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Hormonal Regulation